bims-proned Biomed News
on Proteostasis in neurodegeneration
Issue of 2026–11–01
eleven papers selected by
Verena Kohler, Umeå University



  1. Transl Neurodegener. 2026 Oct 28. pii: 58. [Epub ahead of print]15(1):
      Neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal dementia (FTD), and Parkinson's disease (PD) are characterized by the accumulation of intrinsically disordered proteins (IDPs), including amyloid-β (Aβ), tau, and α-synuclein (αSyn). These proteins disrupt neuronal homeostasis through toxic aggregation, impaired proteostasis, and progressive neurodegeneration, in part via dysfunction of the autophagy-lysosomal pathway (ALP). A central feature of this impairment is defective vacuolar-type (H+)-ATPase (V-ATPase) function, leading to lysosomal deacidification and reduced degradative capacity. Pathological IDP species converge on V-ATPase through direct interactions with its subunits or by perturbing its assembly, while also exerting protein-specific effects, including lysosomal membrane destabilization, impaired hydrolase activity, and disrupted endolysosomal trafficking. These combined mechanisms create a reciprocal relationship between lysosomal dysfunction and IDP accumulation, in which impaired lysosomal degradation further promotes the persistence and aggregation of pathological IDP species. This review synthesizes current insights into the molecular interplay between IDPs and lysosomal acidification across AD, FTD, and PD, and highlights how these processes contribute to disease progression. We further discuss emerging therapeutic strategies aimed at restoring lysosomal function. These findings underscore lysosomal dysfunction as a common feature of IDP-driven neurodegeneration and a potential therapeutic target across these disorders.
    Keywords:  Autophagy; Intrinsically disordered proteins; Lysosomal acidification; Neuroinflammation and neurodegeneration; Protein degradation; Therapeutic strategies
    DOI:  https://doi.org/10.1186/s40035-026-00591-z
  2. ACS Bio Med Chem Au. 2026 Oct 21. 6(5): 508-521
      Although some symptoms of Parkinson's disease can be pharmacologically alleviated, stopping disease progression is not currently possible. Motor impairment in Parkinson's disease is associated with accumulation of aggregates of the protein α-synuclein (α-syn) in dopaminergic neurons in the brain. In some Parkinson's disease cases, these pathogenic aggregates accumulate in the intestinal lining years before motor symptoms manifest. This long prodromal period provides a window of opportunity to detect Parkinson's disease and halt its progression. Specifically, elucidating the factors involved in disease onset in the gut would enable prevention of α-syn aggregation before it spreads to the brain. In this perspective, we highlight discoveries of gut bacteria that induce aggregation of intestinal α-syn as well as efforts to decipher the molecular-level mechanisms by which this process occurs. We also showcase the rationale and potential breadth of applications focused on manipulating the gut microbiome, including biotics, fecal microbiome transplants, and microbial editing. By understanding molecular mechanisms of intestinal α-syn aggregation, the microbiome may be harnessed to control the factors responsible for their pathogenic formation and spread. Such insights will ultimately enable the development of more effective therapeutics for prevention and treatment of Parkinson's disease.
    Keywords:  Parkinson’s disease; gut microbiome; microbial dysbiosis; microbiome-based therapeutics; α-synuclein
    DOI:  https://doi.org/10.1021/acsbiomedchemau.6c00110
  3. J Am Chem Soc. 2026 Sep 23. 148(37): 39591-39608
      Misfolding and aggregation of α-synuclein (α-syn) are central to Parkinson's disease (PD) pathology and are increasingly believed to be modulated by lipid-rich cellular environments. Electrostatic interactions between α-syn and anionic lipids play a key role in membrane binding and can significantly influence aggregation, yet the mechanisms by which physiologically relevant changes in membrane charge regulate the structure and dynamics of membrane-associated α-syn remain incompletely understood. Here, we investigate how membrane electrostatics reshape the conformational ensemble of membrane-bound α-syn using residue-resolved magic-angle spinning (MAS) NMR, Thioflavin T (ThT) aggregation assays, and transmission electron microscopy (TEM). Proteoliposomes made of 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) containing 40%, 35%, or 25% anionic lipid were used to systematically vary bilayer surface charge. MAS NMR measurements show a progressive, charge-dependent redistribution of the α-syn structural ensemble. At a high 40% membrane negative charge, α-syn adopts a primarily α-helical membrane-associated conformation, where the N-terminal region and the aggregation-prone non-amyloid-β component (NAC) domain stay bound to the bilayer, while the C-terminus remains flexible. As bilayer negative charge decreases to 35% and 25% anionic lipid, electrostatic interactions weaken, and the NAC-proximal segments increasingly detach from the membrane, leading to helix-to-coil transitions and greater solvent exposure of residues that have been shown to form the core of α-syn fibrils. ThT aggregation assays, coupled with TEM analysis, reveal that these charge-dependent conformational redistributions correlate with faster primary nucleation, differences in fibril morphology, and higher-order organization. Finally, super-resolution imaging in primary neurons shows that aggregated α-syn accumulates on phosphatidic acid (PA)-enriched mitochondria-derived vesicles, providing a cellular context for the electrostatic regime examined in the model membrane system. Together, our results identify a membrane charge density of 25-35% anionic lipid range as an electrostatic transition region in which the aggregation-prone NAC domain becomes solvent-exposed while the N-terminal anchor remains membrane-associated. These findings provide a residue-level framework for how membrane electrostatics shape the conformational landscape of membrane-bound α-syn and define aggregation-competent states in lipid environments.
    DOI:  https://doi.org/10.1021/jacs.6c08246
  4. Front Neurol. 2026 ;17 1891393
      The accumulation of α-synuclein (α-syn) in the form of Lewy bodies and Lewy neurites is a neuropathological hallmark of Parkinson's disease (PD) and is closely associated with disease progression. Targeting the autophagy pathway to enhance the clearance of α-syn aggregates therefore represents a promising therapeutic strategy. In the present study, we conducted high-throughput screening using rat embryonic primary neurons, followed by validation of the identified compounds in human induced pluripotent stem cell (iPSC)-derived neurons. We identified dibucaine, a local anesthetic, as a compound that induced autophagic flux in neuronal models. In human iPSC-derived dopaminergic neurons from a patient with PD carrying an SNCA duplication, dibucaine reduced cellular levels of Ser129-phosphorylated α-synuclein (pS129 α-syn). In SH-SY5Y cells, dibucaine increased 5'-AMP-activated protein kinase (AMPK) Thr172 phosphorylation. LY364947 partially attenuated dibucaine-induced LC3-II accumulation in the iPSC-derived neurons through an unidentified mechanism. Although the requirement for AMPK and the mechanism underlying the reduction in pS129 α-syn remain unresolved, our findings show that dibucaine induces autophagic flux and reduces pS129 α-syn levels in disease-relevant human neurons.
    Keywords:  Parkinson’s disease; alpha-synuclein; autophagy; dibucaine; neurodegenerative disease; protein aggregation
    DOI:  https://doi.org/10.3389/fneur.2026.1891393
  5. J Am Chem Soc. 2026 Oct 07. 148(39): 41717-41723
      Tau and α-Synuclein (αSyn) frequently coaggregate in various neurodegenerative disorders. Recently, Tau has been shown to form dynamic, liquid-like condensates that can recruit αSyn, and potentially serve as a precursor to pathological crosstalk and aggregation. However, the quantitative impact of αSyn on the material properties of these condensates remains elusive. Here, we measure the viscosity and interfacial tension of Tau condensates and determine how these properties are modulated by αSyn monomers and fibril seeds. We find that while both forms of αSyn partition efficiently into Tau condensates, they exert vastly different effects on the condensate's material state. The viscosity of Tau condensates remains unchanged in the presence of αSyn monomers at concentrations up to 200 μM, accompanied by a moderate reduction in the condensates' interfacial tension. In contrast, adding just 5 μM αSyn fibril seeds triggers rapid maturation of Tau condensates, manifested by a nearly 100-fold increase in their steady-state viscosity within 1 h. These findings provide quantitative insights into condensate mechanics, highlighting the unique capacity of αSyn seeds to modulate Tau condensate viscosity, which may underlie the formation of pathological aggregates.
    DOI:  https://doi.org/10.1021/jacs.6c07726
  6. J Phys Chem B. 2026 Oct 29. 130(43): 11515-11528
      Natural polyphenols are among the most frequently investigated small molecules showing promising therapeutic effects against neurodegenerative diseases. However, drawbacks such as poor aqueous solubility and bioavailability have significantly restricted the biological applications of polyphenols, leading to research to overcome these limitations. Deep eutectic solvents (DESs) are a new class of green and biocompatible solvents with multiple applications, including their use to increase the aqueous solubility and bioavailability of natural polyphenols. This finding motivated us to investigate the effect of ethaline, a DES composed of choline chloride and ethylene glycol, on the capacity of quercetin in modulating the cytotoxic amyloid fibrillation of α-synuclein (α-syn). The results showed that dissolving quercetin in ethaline considerably increased the potential of quercetin to inhibit cytotoxic fibril formation of α-syn. We suggest that increasing the aqueous solubility of quercetin is likely the main mechanism contributing to the beneficial effects of ethaline. Thanks to its enhanced aqueous solubility, quercetin would interact more effectively with surrounding molecules, including α-syn monomers and reactive oxygen species. This increases not only the anti-amyloidogenic effects of quercetin, but can also improve its antioxidant activity, leading to more effective inhibition of α-syn fibrillation process as well as protecting cells against damage induced by α-syn aggregates. These findings may suggest that DESs could serve as new candidates to increase the therapeutic effects of polyphenols in relation to neurodegenerative diseases, including Parkinson's disease.
    DOI:  https://doi.org/10.1021/acs.jpcb.6c04016
  7. Nutrients. 2026 Oct 09. pii: 3304. [Epub ahead of print]18(20):
      Parkinson's disease (PD) is increasingly recognized as a heterogeneous neurodegenerative disorder with multiple clinical and pathological trajectories. In a subset of patients, α-synuclein pathology may begin in the gut and subsequently spread to the brain, a pathway most relevant to the proposed body-first subtype of PD. Tea catechins, particularly epigallocatechin-3-gallate (EGCG), can influence α-synuclein aggregation, oxidative stress, inflammatory signaling, and gut microbial ecology. Because their systemic bioavailability is limited, substantial amounts reach the intestine and undergo microbiota-dependent biotransformation. This review examines whether parent catechins and their microbial metabolites could modify intestinal processes relevant to α-synuclein misfolding and seeding. Evidence indicates that catechins are converted into phenyl-γ-valerolactones and lower-molecular-weight phenolic metabolites, while microbial amyloids such as curli can promote α-synuclein aggregation in experimental models. EGCG can also remodel α-synuclein assemblies, and catechin exposure can alter microbial and inflammatory phenotypes. However, direct evidence that catechin-derived microbial metabolites inhibit curli-α-synuclein cross-seeding or reduce enteric α-synuclein seeding remains limited. By distinguishing general neuroprotection from effects on aggregation, seeding, and disease modification, this review integrates current evidence and highlights the potential relevance of microbiota-dependent catechin metabolism to gut-origin α-synuclein pathology and body-first PD.
    Keywords:  body-first Parkinson’s disease; cross-seeding; curli; epigallocatechin-3-gallate; gut microbiota; gut-origin α-synuclein pathology; microbial metabolites; tea catechins; α-synuclein seeding
    DOI:  https://doi.org/10.3390/nu18203304
  8. bioRxiv. 2026 Aug 31. pii: 2026.08.28.747883. [Epub ahead of print]
      Neurodegenerative diseases are increasingly associated with vascular dysfunction beyond progressive neuronal degeneration, yet how vascular pathology contributes to disease progression remains poorly understood, largely due to the lack of a neurodegenerative disease model capable of capturing neuronal pathology alongside associated vascular dysfunction. Here, we developed a microengineered 3D vascularized brain tissue model that integrates neurospheroids with a self-assembled, perfusable vascular network to recapitulate key features of the neurovascular interface. Using this model, we investigated the vascular contribution to Parkinson's disease pathology by introducing α-synuclein preformed fibrils into the engineered vasculature. Intravascular α-syn fibril exposure induced endothelial barrier disruption, vascular leakage, inflammation, and vascular regression. Notably, this vascular insult was accompanied by intraneuronal α-synuclein aggregation within neurospheroids, suggesting that vascular dysfunction may facilitate the exposure of neural tissue to pathogenic α-synuclein. Our neurodegenerative disease modeling approach establishes a versatile and tractable platform for investigating vascular contributions to neurodegenerative disease progression.
    DOI:  https://doi.org/10.64898/2026.08.28.747883
  9. bioRxiv. 2026 Oct 09. pii: 2026.10.08.757173. [Epub ahead of print]
      Tau amyloid fibrils adopt disease-specific structures across tauopathies, yet the sequence determinants that favor one pathological fold over another remain poorly defined. Here we combine computational saturation mutagenesis and energetic profiling, in vitro aggregation, cryo-EM and cellular seeding assays to identify sequence changes that alter tau fold compatibility. Across six tauopathy fibril structures, approximately 12,000 substitutions revealed that mutational sensitivity is concentrated within interaction networks formed by amyloidogenic motifs rather than uniformly distributed across the fibril core. Comparison of Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE) folds identified residues within the 335-363 region that differentially influence fold compatibility. The S341L/S352I double mutant accelerated aggregation and remodeled packing within the PAM4-containing amyloidogenic region, producing an alternative amyloid architecture in a minimal tau fragment. S341L/S352I biosensors preferentially responded to CTE-derived over Alzheimer's disease-derived seeds, while aggregates generated from recombinant S341L/S352I tau exhibited CTE-like cellular templating behavior. Although these assemblies are not established to reproduce the atomic CTE fold, the results demonstrate that targeted sequence changes can bias tau aggregation and propagation toward a CTE-compatible state. This framework provides a strategy for defining sequence-structure relationships in polymorphic amyloids and developing conformation-selective models and biosensors.
    DOI:  https://doi.org/10.64898/2026.10.08.757173
  10. Pharmaceutics. 2026 Oct 07. pii: 1266. [Epub ahead of print]18(10):
      Aging is associated with a progressive loss of proteostasis and increased susceptibility to neurodegenerative and metabolic disorders. Among the molecular mechanisms implicated in these processes, protein persulfidation, a hydrogen sulfide (H2S)-mediated cysteine modification, has emerged as a critical regulator of protein function and redox homeostasis. Recent studies demonstrate that aging is accompanied by a decline in persulfidation and a concomitant increase in irreversible cysteine hyperoxidation, leading to protein dysfunction and aggregation. Beyond its established role in protecting proteins from oxidative damage, persulfidation has recently been shown to regulate biomolecular condensation and liquid-liquid phase separation, suppressing the formation of pathological protein assemblies linked to aging and neurodegenerative diseases. Moreover, pharmacological approaches that enhance persulfidation, including stimulation of endogenous H2S production and treatment with ergothioneine, improve metabolic resilience, increase NAD+ levels, and promote healthspan in experimental models. In this review, we discuss emerging evidence linking loss of persulfidation to protein aggregation, biomolecular condensates, and age-related functional decline, and highlight therapeutic strategies aimed at restoring persulfidation as a promising avenue for healthy aging and disease intervention.
    Keywords:  aging; biomolecular condensates; cysteine hyperoxidation; cysteine sulfonylation-mediated aggregation; ergothioneine; healthspan; hydrogen sulfide; liquid–liquid phase separation; neurodegeneration; oxidative stress; persulfidation; protein aggregation
    DOI:  https://doi.org/10.3390/pharmaceutics18101266
  11. Biomolecules. 2026 Oct 09. pii: 1470. [Epub ahead of print]16(10):
      Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the loss of motor neurons and widespread neural dysfunction. Loss of serotonin (5-HT) signaling and TAR DNA-binding protein 43 (TDP-43) dysfunction have both been identified as contributing factors to disease progression, although their relationship has yet to be fully defined. The objective of this review was to assess whether any mechanistic links exist between serotonergic dysfunction and TDP-43 proteinopathy in ALS. A scoping review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Databases were queried for the peer-reviewed literature concerning ALS pathophysiology, 5-HT, and TDP-43 (1946 to January 2026). Articles were screened and data independently extracted by two reviewers, which were subsequently synthesized qualitatively (n = 14). The current literature suggests that serotonergic dysfunction can be identified early in ALS pathology, indicated by decreased 5-HT concentration, degeneration of raphe projections, and changes in receptor activity. TDP-43 proteinopathy is a defining characteristic of ALS progression, characterized by cytoplasmic mislocalization and aggregation of TDP-43. Additionally, studies have identified bidirectional links between these dysfunctions: TDP-43 impairs serotonergic transmission, and 5-HT deficiency may drive pathological TDP-43 aggregation. Many mechanisms affected by both serotonergic and TDP-43 dysfunction are associated with disease progression including excitotoxicity, metabolic disturbances, and network hyperexcitability. Despite this, there is a lack of direct experimental evidence elucidating connections between these pathologies. Serotonergic dysfunction and TDP-43 proteinopathy may be linked by shared mechanisms in ALS, though specific causality has not been identified. Further research should aim to clarify the connection between these processes and discover therapeutic targets.
    Keywords:  TAR DNA-binding protein 43 (TDP-43); amyotrophic lateral sclerosis (ALS); protein aggregation; serotonergic dysfunction; serotonin (5-HT); serotonin receptor (5-HTR)
    DOI:  https://doi.org/10.3390/biom16101470